EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Safety and Efficacy of Nerandomilast in Patients With Pulmonary Fibrosis: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Humna Shahzad, Usama Afzaal, Fahad Saleem, Ahmad Hassan Gul, Freya Thummar, Hafiz Nadir Murtaza, Abel Gelan, Maria Ahsan, Rafay Irfan, Ahmad Nawaz, Uzair Jafar, Asma'a Munasar Ali Alsubari, Muhammad Ehsan, Ahmed Nadeem, Praveen Kumar Komminni, Juan Iribarren

The Clinical Respiratory Journal · 2026-03 · 20 (3)

DOI: 10.1111/crj.70181 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Objective Nerandomilast, an oral phosphodiesterase‐4 (PDE4) inhibitor, has shown potential in slowing the progression of pulmonary fibrosis. This meta‐analysis evaluated the efficacy and safety of nerandomilast in preserving lung function among patients with pulmonary fibrosis. Methods MEDLINE, Embase, the Cochrane Library, and ClinicalTrials.gov were systematically searched for randomized controlled trials (RCTs) comparing nerandomilast with placebo. Study quality was assessed using the Cochrane Risk of Bias 2.0 tool. Analyses were performed in RevMan 5.4 using random‐effects models with risk ratios (RR) and mean differences (MD) as effect measures. Results Four RCTs ( n = 2515) were included. Nerandomilast significantly attenuated the decline in forced vital capacity (FVC) compared with placebo (MD: 69.25 mL, 95% CI: 52.1–86.29), but did not improve diffusing capacity for carbon monoxide (DLCO) (MD: 0.84, 95% CI: −0.56 to 2.24). It was associated with a lower pooled risk of all‐cause mortality (RR: 0.68, 95% CI: 0.52–0.88) without increasing adverse events (RR: 1.00, 95% CI: 0.98–1.02) or serious adverse events (RR: 0.93, 95% CI: 0.76–1.14). Conclusion Nerandomilast appears to slow lung function decline in pulmonary fibrosis without added safety risks. Although a lower pooled risk of mortality was observed, individual trials were not powered for mortality outcomes, and event rates were low; therefore, this finding should be interpreted cautiously. Given the heterogeneity of pulmonary fibrosis phenotypes and trial designs, further large‐scale RCTs should explore standardized outcomes, subgroup effects, and combination strategies with nintedanib or pirfenidone.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →